Display options
Cite
Lin M, Alnaggar M, Liang S, et al. An important discovery on combination of irreversible electroporation and allogeneic natural killer cell immunotherapy for unresectable pancreatic cancer. Oncotarget. 2017;8(60):101795-101807doi: 10.18632/oncotarget.21974.
Lin, M., Alnaggar, M., Liang, S., Wang, X., Liang, Y., Zhang, M., Chen, J., Niu, L., & Xu, K. (2017). An important discovery on combination of irreversible electroporation and allogeneic natural killer cell immunotherapy for unresectable pancreatic cancer. Oncotarget, 8(60), 101795-101807. https://doi.org/10.18632/oncotarget.21974
Lin, Mao, et al. "An important discovery on combination of irreversible electroporation and allogeneic natural killer cell immunotherapy for unresectable pancreatic cancer." Oncotarget vol. 8,60 (2017): 101795-101807. doi: https://doi.org/10.18632/oncotarget.21974
Lin M, Alnaggar M, Liang S, Wang X, Liang Y, Zhang M, Chen J, Niu L, Xu K. An important discovery on combination of irreversible electroporation and allogeneic natural killer cell immunotherapy for unresectable pancreatic cancer. Oncotarget. 2017 Oct 19;8(60):101795-101807. doi: 10.18632/oncotarget.21974. eCollection 2017 Nov 24. PMID: 29254205; PMCID: PMC5731915.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Oct 19;8(60):101795-101807. doi: 10.18632/oncotarget.21974. eCollection 2017 Nov 24.

An important discovery on combination of irreversible electroporation and allogeneic natural killer cell immunotherapy for unresectable pancreatic cancer.

Oncotarget

Mao Lin, Mohammed Alnaggar, Shuzhen Liang, Xiaohua Wang, Yinqing Liang, Mingjie Zhang, Jibing Chen, Lizhi Niu, Kecheng Xu

Affiliations

  1. Fuda Cancer Hospital, School of Medicine, Jinan University, Guangzhou, China.
  2. Fuda Cancer Institute, Guangzhou, China.
  3. Hank Bioengineering Co., Ltd, Shenzhen, China.

PMID: 29254205 PMCID: PMC5731915 DOI: 10.18632/oncotarget.21974

Abstract

PURPOSE: To study the safety and clinical efficacy on combination of irreversible electroporation and allogeneic natural killer cell therapy for treating Stage III/IV pancreatic cancer, evaluating median progression free survival (PFS), and overall survival (OS).

RESULTS: Adverse events of all patients were limited to grades 1 and 2, including local (mainly tussis 13.4%, nausea and emesis 7.1%, pain of puncture point 29.6% and duodenum and gastric retention 4.3%) and systemic (mainly fatigue 22.3%, fever 31.6%, and transient reduction of intraoperative blood pressure 25.1% and white cell count reduction 18.3%) reactions, fever was the most frequent. The serum amylase level at 24 h and 7 d after IRE was not significantly changed compared to those before IRE (

MATERIALS AND METHODS: Between July 2016 and May 2017, we enrolled 71 patients who met the enrollment criteria. The patients were divided into stage III (32 patients, 17 patients received only IRE and 15 patients received IRE-NK (Irreversible electroporation- natural killer): 8 patients underwent a course of NK and 7 patients underwent ≥ 3 courses) and stage IV (39 patients, 22 patients received only IRE and 17 patients received IRE-NK: 9 patients underwent a course of NK and 8 patients underwent ≥ 3 courses). The safety and short-term effects were evaluated firstly, then the median PFS, median OS, response rate (RR) and disease control rate (DCR) were assessed.

CONCLUSIONS: Combination of irreversible electroporation and allogeneic natural killer cell immunotherapy significantly increased median PFS and median OS in stage III pancreatic cancer and extended the median OS of stage IV pancreatic cancer. Multiple allogeneic natural killer cells infusion was associated with better prognosis to stage III pancreatic cancer.

Keywords: allogeneic natural killer cell; clinical efficacy; irreversible electroporation; pancreatic cancer

Conflict of interest statement

CONFLICTS OF INTEREST We declared that we have no conflicts of interest.

References

  1. Int J Immunopharmacol. 1999 Feb;21(2):79-101 - PubMed
  2. N Engl J Med. 2000 Oct 26;343(17):1217-22 - PubMed
  3. Transplantation. 2007 Dec 15;84(11):1527-33 - PubMed
  4. Ann Thorac Surg. 2005 Jan;79(1):318-22; discussion 322 - PubMed
  5. Radiology. 2005 Jun;235(3):728-39 - PubMed
  6. Semin Intervent Radiol. 2014 Jun;31(2):111-7 - PubMed
  7. BMC Immunol. 2010 Jan 20;11:3 - PubMed
  8. Ann Surg Oncol. 2016 May;23 (5):1736-43 - PubMed
  9. Anticancer Res. 2003 Nov-Dec;23(6a):4443-9 - PubMed
  10. Br J Surg. 2015 Feb;102(3):182-93 - PubMed
  11. Curr Opin Oncol. 2013 Mar;25(2):115-20 - PubMed
  12. Clin Cancer Res. 2014 Jun 1;20(11):3003-11 - PubMed
  13. PLoS One. 2014 Sep 30;9(9):e108958 - PubMed
  14. Expert Rev Anticancer Ther. 2008 Jun;8(6):993-1002 - PubMed
  15. N Engl J Med. 2012 Jun 28;366(26):2443-54 - PubMed
  16. Cancer Lett. 2014 May 1;346(2):273-7 - PubMed
  17. Mol Clin Oncol. 2014 Sep;2(5):685-694 - PubMed
  18. Lancet Oncol. 2012 Jul;13(7):e301-10 - PubMed
  19. J Gastrointest Surg. 2013 Oct;17(10):1850-6 - PubMed
  20. J Vasc Interv Radiol. 2012 Dec;23 (12 ):1613-21 - PubMed
  21. World J Gastroenterol. 2014 Mar 7;20(9):2267-78 - PubMed
  22. Nat Rev Immunol. 2007 May;7(5):329-39 - PubMed
  23. Cell. 2011 Mar 4;144(5):646-74 - PubMed
  24. Onco Targets Ther. 2015 Jun 22;8:1553-9 - PubMed
  25. Pancreas. 2017 Feb;46(2):e12-e14 - PubMed
  26. J Vasc Interv Radiol. 2005 Jun;16(6):765-78 - PubMed
  27. Ann Surg Oncol. 2013 Dec;20 Suppl 3:S443-9 - PubMed
  28. Curr Opin Immunol. 2004 Oct;16(5):626-33 - PubMed
  29. Immunol Lett. 2017 Apr;184:98-104 - PubMed
  30. Ann Surg Oncol. 2013 Dec;20(13):4305-11 - PubMed
  31. Pancreas. 2013 Oct;42(7):1143-9 - PubMed
  32. Dig Surg. 2015;32(2):90-7 - PubMed
  33. Tumour Biol. 2014 Feb;35(2):987-94 - PubMed
  34. Cancer Metastasis Rev. 2016 Dec;35(4):525-546 - PubMed
  35. J Thorac Dis. 2012 Aug;4(4):408-19 - PubMed
  36. Adv Immunol. 2006;90:51-81 - PubMed
  37. Vox Sang. 2006 Jan;90(1):10-20 - PubMed
  38. J Immunother. 2012 Feb-Mar;35(2):189-95 - PubMed
  39. J Gastrointest Oncol. 2015 Jun;6(3):329-35 - PubMed
  40. Blood. 2005 Jul 1;106(1):376-83 - PubMed
  41. Eur J Cancer. 2009 Jan;45(2):228-47 - PubMed
  42. Ann Surg. 2015 Sep;262(3):486-94; discussion 492-4 - PubMed
  43. Cancer Immunol Immunother. 2012 Nov;61(11):2125-33 - PubMed
  44. N Engl J Med. 2005 Jun 23;352(25):2640-2 - PubMed
  45. BMC Cancer. 2014 Apr 10;14:251 - PubMed
  46. Xenotransplantation. 2009 Jan-Feb;16(1):19-26 - PubMed
  47. Cell Mol Immunol. 2013 May;10(3):230-52 - PubMed
  48. World J Gastroenterol. 2013 Jun 14;19(22):3473-80 - PubMed
  49. Mol Cancer Ther. 2014 Dec;13(12):3152-62 - PubMed
  50. J Surg Oncol. 2016 Dec;114(7):865-871 - PubMed
  51. Cancer. 1981 Jan 1;47(1):207-14 - PubMed
  52. Cancer Res. 2013 Apr 15;73(8):2381-8 - PubMed
  53. J Am Acad Dermatol. 2012 Nov;67(5):1025-39 - PubMed
  54. Cancer Immunol Immunother. 2011 Oct;60(10):1497-502 - PubMed
  55. Cancer Immunol Immunother. 2013 Jan;62(1):65-73 - PubMed

Publication Types